IBM 's Watson Genomics is being added to Illumina 's TruSight Tumor 170 , a tool that matches cancer patients with drugs that might help them . Steve Harvey , vice president of IBM Health , said that some two million Americans could benefit from having their cancer DNA sequenced , but fewer than 1 % do . The aim of the partnership is to make it easier for hospitals to get started with DNA sequencing . The DNA sequencer analyses the 170 genes in the tumour and within hours , Watson produces a report indicating whether a medicine currently available might prove effective .
IBM's Watson Genomics is being added to Illumina's TruSight Tumor 170, a tool that matches cancer patients with drugs that might help them. Steve Harvey, vice president of Watson Health, said that some two million Americans would benefit from having their tumour DNA sequenced, but fewer than 10% do. The aim of the partnership is to make it easier for hospitals to get started with DNA sequencing. The DNA sequencer analyses the 170 genes in the tumour and within minutes, Watson produces a report indicating whether a medicine currently available might prove effective.